T RM cells are noncirculating lymphocytes that preferentially localize to sites of pathogen entry. T RM cells are critical mediators of antipathogen immunity and are becoming recognized as key players in cancer, autoimmune and allergic pathologies 1, 2 . These cells exist in most organs and tissues in both humans and mice, and are found at high densities at sites of previous infection or inflammation [3] [4] [5] . T RM cells are generated from precursors that are transiently present in the circulation, and they are phenotypically distinct from circulating memory T cells (T CIRCM cells), with a unique transcriptional profile that is acquired during differentiation in the tissue [6] [7] [8] [9] . Their restricted anatomical localization and unique gene expression program enable T RM cells to mediate local immunosurveillance and rapid protection against reinfection. Local antigen-sensing by T RM cells can also result in the enhanced recruitment of both adaptive and innate circulating cells to the site of T RM cell activation [10] [11] [12] . However, surprisingly little is known regarding the fate of T RM cells after secondary pathogen encounter. It is not known whether T RM cells persist into secondary memory after recall responses, or whether pre-existing T RM cells are displaced by 'new' T RM cell populations generated after subsequent infections. It is also unclear whether reactivation of T RM cells can lead to re-entry into the recirculating pool.
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Skin T RM cells persist in the epidermis, where they remain at the site of initial lodgment without diffusing through the tissue 13, 14 . Skin T RM cells show minimal evidence of turnover in the steady state 15 , depend uniquely on fatty acid metabolism 16 and express molecules associated with inhibitory T cell function. Therefore, it might be expected that T RM cells are terminally differentiated and unable to expand and survive after recall. Here we examined the T RM cell response to secondary viral infection, using experimental approaches that enabled us to compare responses by T RM cells and T CIRCM cells. We used a model of herpes simplex virus type 1 (HSV) infection that infects the skin before entering the sensory ganglia, where it emerges via zositeriform spread as a band of lesions over the dermatome that is innervated by a single nerve 17 . T RM cells in the tissue can block peripheral HSV replication indirectly by affecting neuronal infection 18 . To determine whether skin-lodged T RM cells can control HSV directly at the skin surface, we reasoned that protection would be confined to regions of skin that contained an area, or 'patch' , of embedded T RM cells. We show that in response to secondary viral infection, T RM cells mediated such local protection, engaged virus-infected cells, remained constrained to their epidermal niche and proliferated in situ. Skin T RM cells were maintained as a stable population after recall. Furthermore, we found that preexisting T RM cells were not displaced by newly recruited T RM cell populations, but instead remained as a numerically stable population in the tissue.
We inoculated the upper flank skin with HSV > 1 cm above the DNFB-treated patch containing gBT-I T RM cells to induce HSV replication and infection of the sensory ganglia ( Supplementary Fig. 1c ). Six days after HSV infection, a band of herpetic lesions spread across the dermatome from the point of inoculation, but the DNFB-treated skin patch remained clear of disease ( Supplementary Fig. 1d ). Viral titers 4 and 6 d after infection were reduced in DNFB-treated skin that contained gBT-I T RM cells compared with those in contralateral skin or in skin of mice treated with DNFB but not those given transfer of gBT-I T cells (Fig. 1a) . Thus, CD8
+ T RM cells can control HSV infection in the skin in a discrete and localized manner.
The density of skin T RM cells influences local immune protection.
After restimulation, T RM cells may facilitate enhanced recruitment of memory T cells from the circulation 12 . We examined whether this was the case after recall of DNFB-lodged skin T RM cells via HSV infection on the DNFB-untreated upper flank. We observed reduced recruitment of CD103 -CD45.1 + gBT-I T cells into DNFBtreated skin containing CD103 + CD45.1 + gBT-I T RM cells 3-6 d after HSV infection compared with that in untreated skin that did not contain gBT-I T RM cells (Fig. 1b) . This indicated that skin T RM cells were dominating local virus protection, in agreement with previous findings showing that T RM cells can protect in the absence of T CIRCM cells [20] [21] [22] [23] . To assess whether this protective response requires an appropriate density of T RM cells to mediate protection, we transferred increasing numbers of Thy1.1 + gBT-I T EFF cells into mice and then subjected them to DNFB-mediated skin lodgment. We allowed the mice to rest for > 30 d and then injected them intraperitoneally (i.p.) with Thy1.1-specific antibody to deplete Thy1.1 + gBT-I T CIRCM cells without affecting skin T RM cells 20 . Increasing the number of input Thy1.1 + gBT-I T cells resulted in a concomitant increase in the number of Thy1.1 + gBT-I T RM cells in DNFB-treated skin (Fig. 1c ) and induced a dose-dependent reduction in viral load 6 d after HSV infection above the DNFB-treated skin patch (Fig. 1d) . Thus, skin T RM cells mediate protection from infection in a manner dependent on their local density in the tissue and independent of circulating T cells.
Antigen-specific T RM cells exhibit dynamic responses to skin infection. To examine how skin T RM cells mediate protection after infection, we transferred in vitro-activated EGFP + gBT-I T cells into mice and then applied DNFB to induce skin lodgment. More than 30 d after EGFP + gBT-I T cell transfer, we imaged the DNFBtreated skin patch by intravital two-photon microscopy (IV-2PM) 24 .
EGFP
+ gBT-I T cells had a dendritic morphology, showed slow migration, and were evenly distributed across the epidermal layer but absent from the dermis in a manner characteristic of skin T RM cells 13 ( Fig. 2a) . To determine whether skin T RM cells can respond to antigen in situ, > 30 d after EGFP + gBT-I T cell transfer and DNFB treatment, we delivered antigen directly into the epidermis by mixing HSV-derived gB peptide with aqueous sorbolene cream and applying it topically to depilated skin 25 . Starting at 3 h after gB peptide application, we observed changes in the dendritic morphology of skin EGFP + gBT-I T RM cells, which became more rounded with shorter dendrites and displayed reduced motility (Fig. 2b,c and Supplementary Video 1). In contrast, application of nonspecific ovalbumin (OVA) peptide did not alter the appearance or motility of skin EGFP + gBT-I T RM cells (Fig. 2b ,c and Supplementary Video 1), which indicates that epidermal T RM cells responded to cognate antigen in situ.
We next examined the localization and migration of T RM cells in DNFB-treated lower flank skin 3-4 d after infection of the DNFBuntreated upper flank skin with HSV-mCherry 26 . After zosteriform spread, we observed small epidermal foci of HSV-mCherry + cells in DNFB-treated skin by 3.5 d after infection, and slow but noticeable spreading of mCherry + HSV over the 4-h imaging period ( Supplementary Fig. 2a ). EGFP + gBT-I T cells clustered near HSV-mCherry + infected cells, whereas epidermal cells distal to virus foci remained evenly distributed ( Supplementary Fig. 2b ). This suggested local accumulation of EGFP + gBT-I T cells in response to the virus, but without the possibility of distinguishing between T RM cells and T cells recruited from the circulation. We also observed highly motile EGFP + gBT-I T cells in the underlying dermis ( Fig. 2d and Supplementary Video 2). EGFP + gBT-I T cells that engaged mCherry + HSV-infected cells showed reduced motility and more restricted migration around the virus foci compared with that of EGFP + gBT-I T cells not recruited to foci of HSV-infected cells (Fig. 2e,f) . Nonspecific EGFP + OT-I T cells transferred to a second group of DNFB-treated mice as a control did not cluster in this manner after mCherry + HSV challenge ( Fig. 2d and Supplementary Video 3) . EGFP + OT-I T RM cells also retained their dendritic morphology, motility and epidermal localization after mCherry + HSV challenge ( Fig. 2d and Supplementary Video 3), which suggested that the changes in T RM cell behavior that we observed during viral recall depended on recognition of cognate antigen. To confirm this, we cotransferred equal numbers of activated EGFP + gBT-I T cells and lymphocyticchoriomeningitis-virus-specific DsRed + P14 T cells (from mice with transgenic expression of the P14 T cell antigen receptor specific for an epitope of lymphocytic choriomeningitis virus glycoprotein) into recipient mice and treated these mice with DNFB to generate skin T RM cells of alternative specificities on the lower flank. Thirty days later, we challenged the mice with CFP + HSV on the upper flank and imaged the DNFB-treated skin by IV-2PM. + gBT-I T CIRCM cells. Ten days after antibody treatment, we infected the mice with HSV-mCherry above the DNFB-treated skin, and 4 d after that we imaged them by IV-2PM. EGFP + gBT-I T RM cells in the mCherry + virus foci adopted a rounded morphology and were more sessile than nearby EGFP + T RM cells that were not in contact with virus-infected cells (Fig. 3a,b and Supplementary Video 4). Although we observed highly motile dermal EGFP + gBT-I T cells in undepleted mice (Fig. 2d and Supplementary Video 2), we did not observe EGFP + gBT-I T cells in the dermis of anti-Thy1.1-treated mice (Fig. 3c) , which indicates that T RM cells responding to challenge within the epidermis did not transit into the dermis.
Next, we directly compared the recall responses of DNFBlodged T RM cells with those mediated by memory T cells recruited from the circulation. To do this, we generated DNFB-recruited skin T RM cells by using gBT-I T cells expressing the photoconvertible protein Kaede, which changes from green fluorescent (Kaede-green) to red fluorescent (Kaede-red) upon exposure to violet light 27 . We infected mice with HSV-CFP above DNFBtreated skin, and 2 d later we exposed the DNFB-treated skin patch to violet light to create Kaede-red + epidermal T RM cells, while unconverted gBT-I T cells in the circulation remained Kaedegreen + . After the spread of HSV to the lower skin flank, on day 3.5, both Kaede-red + and Kaede-green + gBT-I T cells accumulated around CFP + HSV foci (Fig. 3d) . Kaede-red + gBT-I T cells that were distal to virus remained evenly distributed and localized to the epidermis, with a lower average velocity compared with that of the predominantly Kaede-green + gBT-I T cells in the dermis (Fig. 3e) . To assess whether T RM cells migrate from skin to lymph nodes during the recall response, we next examined the distribution of photoconverted and unconverted gBT-I T cells in the skin and draining axillary lymph node 4-5 d after infection with HSV. The majority (91% ± 4.6%) of gBT-I T cells in the skin 4 d after HSV infection were Kaede-red + (Fig. 3f,g ), which indicated that these cells were resident in the skin before viral spread. On day 5 after infection, we observed a greater proportion (34% ± 25%) of Kaede-green + gBT-I T cells in the skin (Fig. 3g ), which indicated recruitment of gBT-I T cells from the circulation. Notably, we could not detect Kaede-red + gBT-I T cells in the draining lymph node at either time point after infection (Fig. 3g) . Moreover, the Kaede-red + gBT-I T cells retained a CD103 + CD69 + T RM cell phenotype, distinct from that of Kaede-green + gBT-I T cells, which were CD103 -CD69 - (Fig. 3h,i) . Together, these data indicate that skin T RM cells that responded to recall virus infection remained constrained to the epidermis and did not migrate into the dermis or local draining lymph nodes. T RM cells proliferate locally in response to antigenic challenge. Phenotypic flow cytometry analysis of gBT-I T RM cells isolated from previously challenged skin > 30 d after HSV infection or DNFB treatment showed increased surface expression of multiple coinhibitory molecules, including PD-1, Tim-3, LAG3, CD101, CD244, CTLA4 and ICOS, compared with that in gBT-I T CIRCM cells ( Supplementary  Fig. 3a ,b). Because these inhibitory receptors are involved in the inhibition of T cell proliferation and effector functions 28 , we tested whether skin T RM cell populations could undergo substantial numerical expansion after challenge. To this end, we generated mice with DNFB-lodged Thy1.1 + gBT-I T RM cells and treated them after > 30 d either with anti-Thy1.1 to deplete gBT-I T CIRCM cells or with PBS as a control. After infecting mice with HSV above DNFBtreated skin, we treated them i.p. with bromodeoxyuridine (BrdU) to assess the proliferative capacity of lodged T RM cells responding to HSV spread ( Supplementary Fig. 4a ). Seven days after HSV infection, we detected a population of circulating CD103
-gBT-I T cells in the DNFB-treated skin of non-antibody-treated control mice, whereas we detected only CD103 + T RM cells in DNFB-treated skin of anti-Thy1.1-treated mice (Fig. 4a) . Notably, a substantial proportion (36% ± 5.4%) of CD103 + gBT-I T RM cells from the skin of Thy1.1-depleted mice had incorporated BrdU 7 d after infection (Fig. 4b,c) . The proliferation marker Ki67 was also upregulated by skin gBT-I T RM cells after infection ( Fig. 4b and Supplementary  Fig. 4b ), which indicates that skin T RM cells proliferated in situ after rechallenge. Ki67 was also upregulated by gBT-I T cells in the spleens of PBS-treated controls after HSV infection ( Supplementary  Fig. 4c ). Divided BrdU + gBT-I T RM cells in DNFB-treated skin of Thy1.1-depleted mice remained CD103 + 7 d after HSV infection ( Supplementary Fig. 4d ), which suggests that T RM cell proliferation expanded or maintained the epidermal T RM cell pool, and that T RM cells did not give rise to CD103 -T cells or lose CD103 expression after stimulation. In a separate approach, we induced skin gBT-I T RM cells from adoptively transferred Thy1.1 + gBT-I naive T cells (T N cells) by epicutaneous skin infection on the lower flank with recombinant vaccinia virus (VV) expressing the HSV gB epitope (VV-gB). After 30 d we treated the mice with anti-Thy1.1 to deplete Thy1.1 + gBT-I T CIRCM cells, and > 7 d after that we infected them with HSV above the primary VV infection site and subsequently treated them with BrdU ( Supplementary Fig. 4a ). We observed increased BrdU incorporation by skin Thy1.1 + gBT-I T RM cells (33.3% ± 4.8%) compared with that in uninfected mice (7.3% ± 2.7%), which indicates that virally primed T RM cells also divide after rechallenge (Fig. 4d) . We also assessed the uptake of BrdU by gBT-I T RM cells 2 d after transcutaneous application of HSV-gB peptide (Fig. 4e) . T RM cells induced by DNFB recruitment or local HSV infection showed similar proliferative responses (45% ± 15% or 42% ± 6.6% BrdU + , respectively) in response to HSV-gB peptide application ( Supplementary Fig. 4e ). Finally, we tested whether skin gBT-I T RM cell proliferation was antigen specific by applying HSV-gB peptide or a nonspecific OVA peptide to the skin of DNFB-treated mice that had also been treated with BrdU, and we observed that division of skin Thy1.1 + gBT-I T RM cells occurred only in response to cognate antigen (Fig. 4f) . Together, these observations indicated that skin T RM cells were not terminally differentiated and divided in situ in response to viral challenge.
However, compared with numbers in uninfected mice, we observed only a marginal increase in the number of Thy1.1 + gBT-I T RM cells in DNFB-treated skin between 3 and 14 d after HSV infection of skin above the DNFB patch ( Supplementary Fig. 4f ). Among the rechallenged gBT-I T RM cell population, we observed an increase in the proportions of annexin V + (from 8.5% ± 0.7% to 18% ± 2.2%) and annexin V + PI + cells (from 7% ± 0.7% to 11% ± 0.9%) 7 d after HSV infection compared with that of DNFB-lodged gBT-I T RM cells at steady state ( Supplementary Fig. 4f,g ), indicative of increased apoptosis of T RM cells after recall in addition to heightened proliferation. In all, these data indicate that T RM cells can be maintained by local proliferation during secondary infections, without the requirement for replenishment from the circulating T cell pool.
Circulating T cells form new T RM cells without displacing preexisting T RM cells. Next, we examined whether antigen-specific memory T cells in the circulation are recruited to inflamed skin and develop into T RM cells after secondary challenge. We also asked how these incoming cells might affect populations of pre-existing T RM cells in the skin. To this end, we carried out antibody-mediated enrichment of CD44 + CD45.1 + gBT-I T CIRCM cells isolated from spleens of mice that were previously infected with HSV, and transferred them into anti-Thy1.1-treated recipient mice with DNFBlodged Thy1.1 + gBT-I skin T RM cells. Two days after CD45.1 + gBT-I T CIRCM cell transfer, we infected the recipient mice with HSV above DNFB-treated skin to restimulate both skin T RM cells and adoptively transferred T CIRCM cells (Supplementary Fig. 5a ). We detected CD45.1 + gBT-I T CIRCM cells in DNFB-treated skin alongside Thy1.1 + gBT-I T RM cells and observed that these cells persisted for at least 30 d after HSV infection (Fig. 5a,b) . CD45.1 + gBT-I T CIRCM cells that infiltrated the skin upregulated both CD69 and CD103 (Fig. 5c) , indicative of de novo T RM cell formation from circulating memory T cell precursors. Stable numbers of Thy1.1 + gBT-I T RM cells were maintained in the DNFB-treated skin before and after HSV challenge, irrespective of CD45.1 + gBT-I T CIRCM transfer (Fig. 5b) , which indicates that the pre-existing skin T RM cell population was not displaced by subsequent T RM cell generation. Together, these findings indicate that both local maintenance of pre-existing T RM cells and de novo differentiation of restimulated T CIRCM cells into T RM cells contribute independently to the maintenance or expansion of the T RM cell pool after secondary infection.
We then sought to determine whether CD8 + T EFF cells of an unrelated specificity would give rise to T RM cells in HSV-infected skin that contained pre-existing T RM cells. We depleted Thy1.1 + P14 T CIRCM cells in mice with DNFB-recruited skin-lodged non-HSVspecific Thy1.1 + P14 T RM cells by administering anti-Thy1.1, and then infected them with HSV above the DNFB patch > 7 d later. Mice received adoptive transfers of in vitro-activated CD45.1 + OT-I T EFF cells and were examined after 30 d (Supplementary Fig. 5b ). HSV infection resulted in recruitment of non-HSV-specific CD45.1 + OT-I T EFF cells into DNFB-treated skin (Fig. 5d,e) , and these bystander CD45.1 + OT-I T EFF cells had converted to a CD69 + CD103 + T RM cell phenotype (Fig. 5f ). The number of pre-existing Thy1.1 + P14 T RM cells in the skin was not affected by CD45.1 + OT-I T EFF cell transfer, despite de novo OT-I T RM cell formation (Fig. 5e) .
Because the presence of local antigen in tissue can influence the formation of T RM cells [29] [30] [31] , we next examined the recall of T RM cells induced by direct skin infection with a virus rather than by DNFB recruitment. We transferred Thy1.1 + gBT-I T N cells into mice, infected the mice on the lower flank skin with VV-gB to generate a population of Thy1.1 + gBT-I T RM cells, and subsequently administered anti-Thy1.1 to deplete Thy1.1 + gBT-I T CIRCM cells. More than 30 d after VV-gB infection and > 7 d after T CIRCM depletion, we challenged the mice with HSV above the initial VV-gB scarification site and transferred in vitro-activated CD45.1 + nonspecific OT-I T EFF cells into them (Supplementary Fig. 5c ). We detected both Thy1.1 + gBT-I T RM cells generated in response to VV-gB infection and bystander CD45.1 + OT-I T RM cells in skin at the previously infected VV-gB site > 30 d after HSV challenge (Fig. 5g-i) . The number of Thy1.1 + gBT-I T RM cells in VV-gB-challenged skin was not changed after HSV infection or by the transfer of bystander OT-I T EFF cells, despite the induction of substantial OT-I T RM cells after HSV infection (Fig. 5h) , which suggests that virally induced T RM cells are also stably maintained after reinfection. Further, to examine recall responses to HSV in the absence of antibody-mediated protection, we infected B-cell-deficient (μ MT) Ighm −/− mice given adoptive transfer of Thy1.1 + gBT-I T N cells with HSV on the lower flank and then treated them with anti-Thy1.1 > 30 d after infection to induce T CIRCM cell depletion. Ten days after T CIRCM cell depletion, we rechallenged the mice with HSV on the upper flank and administered in vitro-activated CD45.1 + OT-I T EFF cells (Supplementary Fig. 5d ). We detected Thy1.1 + gBT-I T RM cells generated by the primary HSV infection in post-lesional skin > 30 d after HSV rechallenge (Supplementary Fig. 5e ). Previously infected skin also contained CD45.1 + OT-I T EFF cells that had converted into CD69 + CD103 + T RM cells, without any effect on the numbers of Thy1.1 + gBT-I T RM cells ( Supplementary Fig. 5e ). Combined, these results show that preexisting and incoming T RM cell populations of identical or different specificities can be maintained and established concomitantly, and do not outcompete one another in the context of local infection.
New T RM cells minimally dislodge pre-existing T RM cells.
To determine whether there is a maximal capacity for T RM cell generation in the skin, we transferred increasing numbers of CD45.1 + gBT-I T EFF cells into mice and induced T RM cell lodgment in the skin with DNFB. Although T cell input in the range of 1 × 10 6 to 100 × 10 6 gBT-I T EFF cells resulted in increasing numbers of splenic gBT-I T cells (Fig. 6a) , the number of skin gBT-I T RM cells plateaued after input of 50 × 10 6 to 100 × 10 6 gBT-I T cells (Fig. 6a) , which indicated that a limited number of T RM cells could be generated in the skin, at least during a single inflammatory response. To test whether subsequent responses could add to the T RM cell pool, we transferred CD45.1 + gBT-I T N cells into mice carrying DNFB-induced skin EGFP + OT-I T RM cells. After > 30 d, we subjected the mice to prime-boost immunization with i.v.-transferred gB-pulsed dendritic cells followed by subcutaneous and intranasal infection with recombinant influenza viruses, which results in widespread generation of skin T RM cells 31 . We left a separate cohort of mice untreated ( Supplementary Fig. 6a ). More than 30 d after influenza virus infection, we detected a pool of newly generated ('new') CD45.1 + gBT-I T RM cells of a different T cell receptor specificity in DNFBtreated skin that also contained 'old' EGFP + OT-I T RM cells (Fig.  6b) . The generation of new T RM cells by multiple-route prime-boost immunization allowed us to assess whether dislodgment of preexisting T RM cells occurred in the absence of perturbation to the skin tissue itself. We detected minimal numerical decay of DNFBinduced 'old' skin EGFP + OT-I T RM cells in prime-boost-immunized mice compared with that in control mice that were not subjected to prime-boost immunization (Fig. 6b) , which indicated that de novo formation of T RM cells with different specificities occurred without displacement of pre-existing T RM cells in the tissue. Moreover, when DNFB-treated mice carrying 'old' CD45.1 + gBT-I T RM cells received adoptively transferred EGFP + OT-I T N cells and 'new' T RM cell formation was induced via multiple skin immunizations (epicutaneous infection with VV-OVA contralateral to DNFB-treated skin followed by secondary VV-OVA infection at an unrelated skin site) ( Supplementary Fig. 6b ), the number of pre-existing CD45.1 + gBT-I T RM cells in the skin remained constant compared with that in nonimmunized mice (Fig. 6c) . Collectively, these findings highlight the exceptional stability of skin T RM cell populations after rechallenge. 
Discussion
Here we found that T RM cells respond in an antigen-specific manner, proliferate and survive after local restimulation, and are not dislodged by newly generated T RM cells. This has important implications for understanding how immune memory is maintained in peripheral tissues. We show that T RM -cell-mediated protection is directly linked to the density of T RM cells in the skin. This finding was predicted by mathematical models that showed an inverse correlation between the number of CD8 + T cells in the genital mucosa after HSV reactivation and the severity of disease 32 . We observed that T RM cells that interacted with virus-infected cells decelerated and were restimulated, whereas T RM cells in nearby uninfected epidermis continued to exhibit random migration. Our imaging did not reveal any obvious attraction of T RM cells to virally infected cells, which suggests that T RM cells need to be in the right place at the right time to protect against infection. Consequently, it may take hours to days for epidermal T RM cells to chance upon infected cells, which highlights the importance of T RM cell density for protection. We found that T RM cells were able to protect against local infection independently of T CIRCM cells, although the mechanism through which T RM cells execute protection is unclear. It has been shown that T RM cells can directly kill infected cell targets 33 . Although we observed skin T RM cells engaging virally infected cells, we were unable to regularly document killing of infected targets by CD8 + T cells in the skin (data not shown). It is possible that the density of T RM cells inversely regulates the recruitment of T cells from the circulation, as near-sterile immunity induced by local T RM cells might negate the need to recruit large numbers of T CIRCM cells and reduce inflammation.
T RM cells proliferated in response to antigen, yet numbers of secondary T RM cells in the absence of T CIRCM cells did not markedly increase. Skin T RM cell populations seemed to maintain their stability by balancing cell death with proliferation, as we observed increased annexin V staining of skin T RM cells after viral recall. Restimulated T RM cells did not exit the epidermis even after proliferation, at least within the first 5 d after reinfection. T RM cells survive poorly when removed from tissues 33 (data not shown), which potentially limits their relocation to other tissues. Collectively, our results indicate that T RM cells, at least in the skin, are a durable and autonomous population. It will, however, be important to ascertain whether T RM cells in other organs are similarly tissue restricted after reactivation, particularly in tissues such as the lungs, where local T RM cell maintenance relies on constant replenishment from circulating cells 34 . We show that T CIRCM cells and T EFF cells are recruited into the skin after pathogen re-encounter; there, some convert into T RM cells, thereby adding to the T RM cell pool. Our findings suggest that T RM cells can be maintained in tissues subject to repeated infections, with unrelated infections unlikely to substantially dislodge T RM cells already in the tissue. Such knowledge is of clinical relevance for vaccine strategies that might induce diverse T RM cells to protect against multiple diseases. Nonetheless, under conditions where T RM cells of certain specificities are undesirable, such as psoriasis in the skin 35, 36 , replacing unwelcome T RM cells with desired T RM cell populations may be a challenge.
Methods
Methods, including statements of data availability and any associated accession codes and refrences, are available at https://doi. org/10.1038/s41590-017-0027-5.
Intravital two-photon microscopy. Mice were anesthetized with isoflurane (Cenvet; 2.5% for induction, 1-1.5% for maintenance, vaporized at an 80:20 mixture of O 2 and air) and then shaved on the left flank and depilated for flank skin imaging as described 42 . Briefly, we made two incisions (~15 mm apart) longitudinally along the left flank, cutting through the dermis, and separated the peritoneum by cutting away the connective tissues underneath the skin. A 18-mm-wide × 1-mm-thick stainless steel platform was inserted under the exposed dermis, which was glued to the platform with Vetbond tissue adhesive (3 M). The edges of the skin were lined with vacuum grease (Dow Corning), upon which a glass coverslip was placed. Imaging was done with an upright LSM710 NLO multiphoton microscope (Carl Zeiss) with a 20 × /1.0 numerical aperture (NA) water-immersion objective enclosed in an environmental chamber that was maintained at 35 °C with heated air. Fluorescence excitation was provided by a Chameleon Vision II Ti:sapphire laser (Coherent) with dispersion correction and fluorescence emission detected by external non-descanned photomultiplier tubes. We excited EGFP and second-harmonic generation at 920 nm, mCherry at 960-980 nm, Kaede-green at 800 nm, and Kaede-red at 900 nm. For four-dimensional datasets, three-dimensional stacks were captured every 1 min for at least 30 min. Raw imaging data were then processed with Imaris 8 (Bitplane), and movies were generated in Imaris and composed in After Effects (Adobe). gBT-I T RM cells were anesthetized, shaved and depilated, and infected with HSVmCherry. At 2 d post-infection, we used a 410-nm spot lamp (Dymax Bluewave LED; UV Pacific) to expose mice to 100 mJ/cm 2 violet light for 6 min. Light emitted through an 8-mm-diameter fiber optic guide was mounted at a distance of 4.17 cm directly above the DNFB patch, and areas around the patch were covered with a double layer of aluminum foil to prevent distal photoconversion. Mice were then imaged by IV-2PM from 94 h post-infection.
Intravital imaging analysis.
Transcutaneous delivery of gB and OVA peptide. We added 50 μ g of MHC-Irestricted HSV gB 498-505 (SSIEFARL) or OVA (SIINFEKL) peptides (Genscript) to 100 mg of sorbolene cream and mixed it thoroughly by successive vortexing and short-pulse centrifugation. Mice containing DNFB-recruited lodged T RM cells were anesthetized, shaved and depilated, and the peptide-sorbolene mixture was applied directly atop the DNFB patch. The peptide-cream mixture was contained above the skin region by a bandage consisting of an adhesive film (OpSite Flexigrid; Smith & Nephew) and surgical tape (Micropore tape; 3 M). For intravital imaging experiments, the mixture was allowed to absorb through the skin for 3 h before removal of the bandage. For flow cytometry experiments, the peptidesorbolene mixture was applied once per day for 2 d, and mice were bandaged for 24 h after each application. 
Data exclusions
Describe any data exclusions. Mice with gBT-I/Thy1.1 cell depletion efficiency <99% in the spleen were excluded from analysis in Supplementary Fig 3c only . This exclusion criteria was chosen to avoid accidental inclusion of contaminating circulating gBT-I cells (CD103-) in the analysis of CD103 expression levels on gBT-I TRM cells incorporating BrdU in the skin.
Replication
Describe whether the experimental findings were reliably reproduced.
Experiments were reliably reproduced and the number of experiments performed stated in methods and legends. All experiments were repeated successfully in this manuscript.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice of the same age/sex were randomly allocated to experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not performed in this study. The experimental observations (viral titer, enumeration, cellular surface phenotypes) would be consistent irrespective of blinding.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Flow cytometry data was analysed using FlowJo 9.9.4 software (Treestar).
Statistical testing was performed in and graphs were generated in Prism 7.0 (Graphpad). Intravital microscopy analysis and compilation was performed in Imparis (Bitplane), tracking analysis performed using Matlab (Mathworks), and movies compiled in After Effects (Adobe).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Any unique materials are available from the authors upon request.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The clone and manufacturer of each antibody used in this study can be found in the Materials & Methods section of this paper. Antibodies were validated according to the manufacturers instructions. b. Describe the method of cell line authentication used. Cells were purchased from a commercial source.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cell lines were tested for mycoplasma contamination and were not contaminated.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
